Literature DB >> 1826560

Nonfunctional mutants of the retinoblastoma protein are characterized by defects in phosphorylation, viral oncoprotein association, and nuclear tethering.

D J Templeton1, S H Park, L Lanier, R A Weinberg.   

Abstract

We have examined the functional consequences of mutations present in defective alleles of the retinoblastoma susceptibility gene (RB1) isolated from two spontaneously arising tumors. Unlike cDNA clones expressing the wild-type protein p110Rb, those encoding the two mutant proteins failed to induce the appearance of senescent cells in transfected Saos-2 human osteosarcoma cells. The mutant proteins were also defective in binding to the E1A oncoprotein, were unable to become hyperphosphorylated, and failed to become tightly associated with nuclear structures. We conclude that mutations in two distinct regions of the protein concomitantly affect these four aspects of p110Rb function.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1826560      PMCID: PMC51378          DOI: 10.1073/pnas.88.8.3033

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  High-efficiency transformation of mammalian cells by plasmid DNA.

Authors:  C Chen; H Okayama
Journal:  Mol Cell Biol       Date:  1987-08       Impact factor: 4.272

2.  SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene.

Authors:  J A DeCaprio; J W Ludlow; J Figge; J Y Shew; C M Huang; W H Lee; E Marsilio; E Paucha; D M Livingston
Journal:  Cell       Date:  1988-07-15       Impact factor: 41.582

3.  Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product.

Authors:  P Whyte; K J Buchkovich; J M Horowitz; S H Friend; M Raybuck; R A Weinberg; E Harlow
Journal:  Nature       Date:  1988-07-14       Impact factor: 49.962

4.  The retinoblastoma protein is phosphorylated during specific phases of the cell cycle.

Authors:  K Buchkovich; L A Duffy; E Harlow
Journal:  Cell       Date:  1989-09-22       Impact factor: 41.582

5.  Purified maturation promoting factor phosphorylates pp60c-src at the sites phosphorylated during fibroblast mitosis.

Authors:  S Shenoy; J K Choi; S Bagrodia; T D Copeland; J L Maller; D Shalloway
Journal:  Cell       Date:  1989-06-02       Impact factor: 41.582

6.  The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product.

Authors:  N Dyson; P M Howley; K Münger; E Harlow
Journal:  Science       Date:  1989-02-17       Impact factor: 47.728

7.  Adenovirus E1a gene product expressed at high levels in Escherichia coli is functional.

Authors:  B Ferguson; N Jones; J Richter; M Rosenberg
Journal:  Science       Date:  1984-06-22       Impact factor: 47.728

8.  Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung.

Authors:  J Yokota; T Akiyama; Y K Fung; W F Benedict; Y Namba; M Hanaoka; M Wada; T Terasaki; Y Shimosato; T Sugimura
Journal:  Oncogene       Date:  1988-10       Impact factor: 9.867

9.  Abnormalities in structure and expression of the human retinoblastoma gene in SCLC.

Authors:  J W Harbour; S L Lai; J Whang-Peng; A F Gazdar; J D Minna; F J Kaye
Journal:  Science       Date:  1988-07-15       Impact factor: 47.728

10.  Point mutational inactivation of the retinoblastoma antioncogene.

Authors:  J M Horowitz; D W Yandell; S H Park; S Canning; P Whyte; K Buchkovich; E Harlow; R A Weinberg; T P Dryja
Journal:  Science       Date:  1989-02-17       Impact factor: 47.728

View more
  74 in total

1.  Serum-induced expression of the cdc25A gene by relief of E2F-mediated repression.

Authors:  X Chen; R Prywes
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

2.  Cumulative effect of phosphorylation of pRB on regulation of E2F activity.

Authors:  V D Brown; R A Phillips; B L Gallie
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

3.  Regions and activities of simian virus 40 T antigen that cooperate with an activated ras oncogene in transforming primary rat embryo fibroblasts.

Authors:  Tina M Beachy; Sara L Cole; Jane F Cavender; Mary J Tevethia
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  The p44/wdr77-dependent cellular proliferation process during lung development is reactivated in lung cancer.

Authors:  Z Gu; F Zhang; Z-Q Wang; W Ma; R E Davis; Z Wang
Journal:  Oncogene       Date:  2012-06-04       Impact factor: 9.867

5.  Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding.

Authors:  Y Qian; C Luckey; L Horton; M Esser; D J Templeton
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

6.  Cellular senescence requires CDK5 repression of Rac1 activity.

Authors:  Kamilah Alexander; Hai-Su Yang; Philip W Hinds
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

7.  Deletion of RB exons 24 and 25 causes low-penetrance retinoblastoma.

Authors:  R Bremner; D C Du; M J Connolly-Wilson; P Bridge; K F Ahmad; H Mostachfi; D Rushlow; J M Dunn; B L Gallie
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

8.  Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation.

Authors:  E S Knudsen; J Y Wang
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

9.  Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines.

Authors:  W Li; J Fan; D Hochhauser; D Banerjee; Z Zielinski; A Almasan; Y Yin; R Kelly; G M Wahl; J R Bertino
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

10.  Further characterization of retinoblastoma gene-mediated cell growth and tumor suppression in human cancer cells.

Authors:  Y Zhou; J Li; K Xu; S X Hu; W F Benedict; H J Xu
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.